Advanced Maternal Age Infertility (>=35 years)
Conditions
Interventions
NICS Group:Thawing—short-term recovery culture—collection of recovery culture medium for NICS testing—re-freezing strategy
in subsequent FET cycles, embryo selection based on NICS-AI grading (A>B>C) combined with morphological assessment, followed by single blastocyst frozen embryo transfer.
Control Group (Traditional Morphology Group):No NICS screening
direct embryo selection based on traditional morphological grading of frozen embryos, followed by single blastocyst frozen embryo transfer.
Sponsors
Hebei Reproductive and Obstetrics Hospital
Eligibility
Sex/Gender
Female
Age
35 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Infertile couples who receive ICSI or IVF assisted reproductive technology, excluding egg/sperm donation cycles; 2. Female age >=35 years old (based on the date of egg retrieval); 3. There is a history of failed embryo transfer (fresh embryo/frozen embryo) (non-pregnancy/biochemical pregnancy/miscarriage/fetal arrest), including 1-2 failed transfers or 1 miscarriage, and the chromosomal test of the miscarriage product is positive. 4. The female body mass index (BMI) is between 18 and 30 kg/m^2. 5. The number of remaining frozen blastocysts is >=2 and the blastocyst days are all D5/D6. Or, after culturing blastocysts from frozen cleaved embryos, the total number of blastocysts tested is >=2. The blastocyst rating should be 4BC/4CB or above. 6. The first transfer after enrollment was single blastocyst transfer; 7. The karyotypes of the couple are normal.
Exclusion criteria
Exclusion criteria: 1. Diseases that are not suitable for IVF or ICSI, such as liver disease, kidney disease, type 1 or type 2 diabetes, heart disease, anemia, poorly controlled hypertension, history of cerebrovascular events, history of deep vein thrombosis and/or pulmonary embolism, history of cervical cancer, endometrial cancer or breast cancer, and undiagnosed vaginal bleeding; 2. Anyone who has undergone or plans to undergo preimplantation genetic testing/screening in previous cycles: PGT-A/PGT-M/PGT-SR (including those to be conducted this time) or has undergone NICS for this batch of embryos in the past; 3. Pathological conditions that may affect pregnancy outcomes, including genital malformations, hydrosalpinx, intrauterine infections, uterine fibroids with a diameter greater than 4 cm, benign pelvic or abdominal tumors with a diameter greater than 4 cm, endometrial thickness less than 7 mm that cannot be improved, pituitary tumors and malignant tumors; 4. Untreated hyperprolactinemia, thyroid diseases and adrenal diseases; 5. Endometrial polyps that were not treated before the thawing and transplantation cycle; 6. Patients with repeated implantation failure (failure to achieve clinical pregnancy after at least three high-quality embryos have been transplanted in three fresh or frozen cycles) and those with repeated miscarriage (two or more consecutive miscarriages before 20 weeks).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Continuing pregnancy rate at 12 weeks of gestation; | — |
Secondary
| Measure | Time frame |
|---|---|
| Clinical pregnancy rate;Spontaneous abortion rate;Live birth rate;Neonatal outcomes; | — |
Countries
China
Contacts
Public ContactCai Liyi
Hebei Reproductive and Obstetrics Hospital
Outcome results
None listed